New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 18, 2012
06:01 EDTAPRIApricus Biosciences receives $2.5M payment from Abbott Laboratories for Vitaros
Apricus Biosciences announced that it received a $2.5M payment from Abbott Laboratories Limited under its commercial partnership for Apricus Bio's Vitaros drug for erectile dysfunction, in Canada. Also, Apricus Bio successfully produced six consecutive commercial size validation batches of Vitaros, the company's treatment for ED in 220 mcg and 330 mcg forms.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
16:34 EDTAPRIApricus Biosciences announces issuance of U.S. patent for RayVa
Apricus Biosciences announced that , January 27, 2015, the United States Patent and Trademark Office, USPTO, issued to Apricus, U.S. Patent No. 8,940,794, titled "METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE," with claims generally directed to methods for treating Raynaud's phenomenon, that is secondary to systemic sclerosis. The patent is expected to expire no earlier than its twenty-year term in 2032. RayVa is the proprietary name for Apricus' product candidate for the treatment of Raynaud's phenomenon. Raynaud's phenomenon is a circulatory disorder affecting the hands and feet. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use